{"id":"NCT04542499","sponsor":"AbbVie","briefTitle":"Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)","officialTitle":"A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-09-23","primaryCompletion":"2024-01-29","completion":"2024-02-15","firstPosted":"2020-09-09","resultsPosted":"2025-03-25","lastUpdate":"2025-04-04"},"enrollment":507,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson Disease"],"interventions":[{"type":"DRUG","name":"Tavapadon","otherNames":["PF-06649751","CVL-751"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tavapadon","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of \"on\" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are experiencing motor fluctuations.","primaryOutcome":{"measure":"Change From Baseline in the Total \"On\" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser Diary)","timeFrame":"Week 26","effectByArm":[{"arm":"Placebo","deltaMin":0.619,"sd":0.188},{"arm":"Tavapadon","deltaMin":1.721,"sd":0.207}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":22},"locations":{"siteCount":146,"countries":["United States","Australia","Bulgaria","Canada","Czechia","France","Germany","Hungary","Israel","Italy","Poland","Serbia","Spain","Ukraine"]},"refs":{"pmids":[],"seeAlso":["https://www.abbvieclinicaltrials.com/study/?id=CVL-751-PD-003"]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":255},"commonTop":["NAUSEA","DYSKINESIA","FALL","DIZZINESS","HEADACHE"]}}